Last edition
News about "anti-tumour activity"
Evexta Bio, Roche Partner to Evaluate Novel Breast Cancer Combination Therapy
Evexta Bio has entered a clinical collaboration with Roche to evaluate its investigational therapy rupitasertib in combination with giredestrant for the treatment of advanced ER+, HER2-, ESR1-mutated breast cancer.
Anti-tumour Activity | 05/08/2026 | By News Bureau
Iksuda Therapeutics Secures US FDA IND Clearance for Novel ADC Candidate IKS04 in GI Cancers
Phase 1 trial to evaluate first-of-its-kind CA242-targeted antibody-drug conjugate with an innovative co-administration regimen designed to improve solid tumour penetration and therapeutic efficacy.
Anti-tumour Activity | 03/08/2026 | By News Bureau
Bio-Thera Doses First Patient in Phase 1 Trial of CD25-Targeting ADC BAT8013
Bio-Thera Solutions has dosed the first patient in a Phase 1 trial of BAT8013, a novel CD25-targeting antibody-drug conjugate designed to enhance anti-tumour immune responses in patients with advanced solid tumours.
Anti-tumour Activity | 27/07/2026 | By News Bureau
D3 Bio has received FDA IND clearance to initiate a Phase I trial of its KRAS G12D inhibitor D3S-003 and a Phase II combination study targeting KRAS G12C-mutant lung cancer.
Anti-tumour Activity | 19/01/2026 | By News Bureau | 687
GSK Gains Exclusive Rights to Syndivia's Prostate Cancer ADC
GSK has obtained exclusive rights from Syndivia for a preclinical Antibody-Drug Conjugate (ADC) targeting metastatic Castration-Resistant Prostate Cancer (mCRPC), addressing an urgent need for novel therapies. The agreement expands GSK’s oncology pipeline with a potential best-in-class ADC designed to deliver enhanced anti-tumour activity.
Anti-tumour Activity | 27/10/2025 | By Dineshwori | 351
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy